One-Time Injection for Geographic Atrophy Due to Dry AMD of the Eye
Evaluating the efficacy, safety, and tolerability of an investigational one-time gene therapy given as a single injection under the retina in adults with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Participants are randomly assigned to receive the investigational therapy or to be followed without treatment, with regular eye exams and imaging over 12 months. Participants in the untreated group may be offered the chance to receive the therapy after the study ends. Participation is voluntary. Transportation to and from study visits is always provided.
12 months, with optional long-term follow-up
Up to $1,200, plus transportation provided
PRIME Trials — All sites
Who may qualify
Adults 55 and older with geographic atrophy from dry AMD, with vision in the study eye between 20/25 and 20/320. Other eye and health criteria apply and will be reviewed by the study team.
Step 1 of 1
Enroll in this study
Answer a few quick questions below and a study coordinator will call you to confirm eligibility. It takes about a minute and there is no obligation.
One-Time Injection for Geographic Atrophy Due to Dry AMD of the Eye
Enter your ZIP code so we can match you to the nearest site.
Prefer to talk now?
Call or text our team and we will walk you through this study.
